Glaucoma Treatment Market 2034: EMA, PDMA, FDA Approvals, Clinical Trials, Medication, Therapies, NICE Approvals, Prevalence, and Companies by DelveInsight

Glaucoma companies are Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
(Albany, USA) DelveInsight's "Glaucoma Market Insights, Epidemiology, and Market Forecast-2034" report delivers an in-depth understanding of Glaucoma, historical and forecasted epidemiology as well as the Glaucoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Glaucoma market report provides current treatment practices, emerging drugs, the market share of the individual therapies, and the current and forecasted Glaucoma market size from 2020 to 2034, segmented by seven major markets. The Report also covers current Glaucoma treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best opportunities and assesses the underlying potential of the Glaucoma market.

Request for a Free Sample Report @ Glaucoma Market Forecast [https://www.delveinsight.com/report-store/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Some facts of the Glaucoma Market Report are:

* According to DelveInsight, Glaucoma market size is expected to grow at a decent CAGR by 2034.
* The total Glaucoma Market Size in the 7MM was around USD 4,073 million in 2022. This is estimated to increase by 2034 at a significant CAGR.
* In April 2025, AbbVie released updates of a Prospective, Multicenter Clinical Study to Evaluate the Safety and Effectiveness of Gel Stent (XEN63) Implantation Using Ab Interno and Ab Externo Approaches in Subjects With Glaucoma
* In March 2025, Qlaris Bio, Inc. announced a Randomized, Active-controlled, Multi-site, Double-masked, Pilot Study to Evaluate the Safety and Tolerability of QLS-111 Versus Timolol Maleate Preservative Free 0.5% Ophthalmic Solution in Subjects with Normal Tension Glaucoma (NTG)
* In February 2025, Alcon announced the US Launch of Voyager DSLT, a first-of-its-kind treatment for glaucoma and ocular hypertension.
* In November 2024, MediPrint Registered Ophthalmics, a clinical-stage ophthalmic drug delivery company based in San Diego, revealed the results of its Phase 2b clinical trial for LL-BMT1. This trial utilized a novel 3D-printed, drug-eluting contact lens designed to deliver bimatoprost and hyaluronic acid for sustained treatment. The trial successfully met all Phase 2b endpoints. Dr. Ian Ben Gaddie presented these findings at the American Academy of Optometry's annual meeting in Indianapolis, emphasizing LL-BMT1's potential as an innovative solution for managing mild to moderate glaucoma while enhancing contact lens comfort and alleviating dry eye symptoms.
* In October 2024, At the American Academy of Ophthalmology (AAO) 2024 conference held in Chicago, Illinois, findings from a Phase II study evaluating the safety of Neurotech Pharmaceuticals' NT-501 encapsulated cell therapy, which secretes ciliary neurotrophic factor (CNTF), were presented. The results were shared by Alexandria M. Dominguez, MS, a research assistant at the Byers Eye Institute at Stanford University. The study indicated that the CNTF-secreting implants were well-tolerated by patients with primary open-angle glaucoma, with no severe adverse events reported. This therapy showed promising potential in managing intraocular pressure (IOP) and supporting retinal health, both of which are essential for effective glaucoma treatment.
* Leading Glaucoma companies working in the market are Allergan, Sun Pharma Advanced Research Company Limited, Santen Pharmaceutical Co., Ltd., D.Western Therapeutics Institute (DWTI), Kowa Ltd., Alcon, Senju Pharmaceuticals and Otsuka Pharmaceuticals Co. Ltd., TearClear, Peregrine Ophthalmic, Envisia Therapeutics, Ocuphire Pharma, Sylentis, Nicox Opthalmics, Santen Pharmaceuticals, Perrigo Company, Bausch and Lomb, Ono Pharmaceutical, Novartis, Merck & Co, Aerie Pharmaceuticals, Ube Industries, and others.
* Key Glaucoma Therapies expected to launch in the market are ROCKLATAN/ ROCLANDA, DURYSTA (bimatoprost SR), NCX-470, TRS01, iDose TR (travoprost intraocular implant), and others.
* On February 2024, Laboratoires Thea announced a study for Safety Assessment of T4090 Eye Drops in Ocular Hypertensive or Glaucomatous Patients.
* On March 2024, Amneal Pharmaceuticals announced a Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint Comparing Generic Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN Registered (Bimatoprost Ophthalmic Solution) 0.01% in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes.

Glaucoma Overview

Glaucoma is a group of eye diseases that cause damage to the optic nerve, often linked to elevated intraocular pressure. Glaucoma symptoms are usually silent in the early stages, making early detection crucial. Glaucoma diagnosis typically involves eye pressure tests, optic nerve imaging, and visual field tests. Glaucoma treatment options range from medicated eye drops to laser procedures and surgery, depending on the severity. Glaucoma medications aim to lower intraocular pressure and prevent further damage. Glaucoma surgery may be recommended when medications and lasers are insufficient.

Glaucoma causes include genetic factors, aging, and certain medical conditions like diabetes or hypertension. Glaucoma types commonly include open-angle glaucoma, angle-closure glaucoma, normal-tension glaucoma, and congenital glaucoma. Glaucoma risk factors increase with age, family history, and specific ethnic backgrounds. Glaucoma prevention focuses on regular comprehensive eye exams, especially for high-risk individuals.

Glaucoma awareness campaigns emphasize early screening and adherence to treatment plans. Glaucoma research continues to explore better therapies and early detection methods. Glaucoma management requires lifelong monitoring to preserve vision and quality of life. Glaucoma progression can be slowed significantly with early and consistent care. Understanding glaucoma facts and maintaining eye health are critical steps toward combating this "silent thief of sight."

Learn more about Glaucoma treatment algorithms in different geographies, and patient journeys. Contact to receive a sample @ Glaucoma treatment market [https://www.delveinsight.com/report-store/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Glaucoma Market

The Glaucoma market outlook of the report helps to build a detailed comprehension of the historical, current, and forecasted Glaucoma market trends by analysing the impact of current Glaucoma therapies on the market and unmet needs, and drivers, barriers, and demand for better technology.

This segment gives a thorough detail of the Glaucoma market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated Glaucoma market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

The Glaucoma market is primarily driven by the rising prevalence of glaucoma worldwide, increasing awareness about early diagnosis, and advancements in treatment options such as innovative drug therapies and minimally invasive surgical devices. Additionally, the aging global population and the growing incidence of diabetes, a major risk factor for glaucoma, further boost the Glaucoma market growth. Supportive government initiatives, improved healthcare infrastructure, and the expansion of teleophthalmology services also contribute positively.

However, the Glaucoma market faces barriers such as the asymptomatic nature of early-stage glaucoma leading to underdiagnosis, high treatment costs, limited access to specialized care in developing regions, and patient non-compliance with long-term therapy. Furthermore, the complexity of developing new glaucoma drugs and regulatory hurdles for approvals present additional challenges. Despite these obstacles, ongoing research and technological advancements continue to offer new opportunities for the Glaucoma market.

According to DelveInsight, the Glaucoma market in 7MM is expected to witness a major change in the study period 2020-2034.

Glaucoma Epidemiology

The Glaucoma epidemiology section provides insights into the historical and current Glaucoma patient pool and forecasted trends for seven individual major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the Glaucoma market report also provides the diagnosed patient pool, trends, and assumptions.

Explore more about Glaucoma Epidemiology @ Glaucoma Market Dynamics and Trends [https://www.delveinsight.com/report-store/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Glaucoma Drugs Uptake

This section focuses on the uptake rate of the potential Glaucoma drugs recently launched in the Glaucoma market or expected to be launched in 2020-2034. The analysis covers the Glaucoma market uptake by drugs, patient uptake by therapies, and sales of each drug.

Glaucoma Drugs Uptake helps in understanding the drugs with the most rapid uptake and the reasons behind the maximal use of new drugs and allows the comparison of the drugs based on Glaucoma market share and size, which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

Glaucoma Pipeline Development Activities

The Glaucoma report provides insights into different therapeutic candidates in Phase II, and Phase III stages. It also analyses Glaucoma key players involved in developing targeted therapeutics.

Request for a sample report to understand more about the Glaucoma pipeline development activities @ Glaucoma Therapies and Drugs [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Glaucoma Therapeutics Assessment

Major key companies are working proactively in the Glaucoma Therapeutics market to develop novel therapies which will drive the Glaucoma treatment markets in the upcoming years are Allergan (NYSE: AGN), Sun Pharma Advanced Research Company Limited (NSE: SPARC), Santen Pharmaceutical Co., Ltd. (TYO: 4536), D.Western Therapeutics Institute (JASDAQ: 4576), Kowa Ltd. (private company), Alcon (SIX: ALC), Senju Pharmaceuticals (private company), Otsuka Pharmaceutical Co., Ltd. (private company), TearClear (private company), Peregrine Ophthalmic (private company), Envisia Therapeutics (private company), Ocuphire Pharma (NASDAQ: OCUP), Sylentis (subsidiary of PharmaMar, BME: PHM), Nicox Ophthalmics (EPA: COX), Santen Pharmaceuticals (TYO: 4536), Perrigo Company (NYSE: PRGO), Bausch and Lomb (NYSE: BLCO), Ono Pharmaceutical (TYO: 4528), Novartis (SWX: NOVN), Merck & Co (NYSE: MRK), Aerie Pharmaceuticals (NASDAQ: AERI, acquired by Alcon), Ube Industries (TYO: 4208), and others.

Request for a sample report to understand more about the Glaucoma Therapeutic landscape @ Glaucoma Clinical Trials and FDA Approvals [https://www.delveinsight.com/sample-request/glaucoma-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=apr]

Glaucoma Report Key Insights

1. Glaucoma Patient Population

2. Glaucoma Market Size and Trends

3. Key Cross Competition in the Glaucoma Market

4. Glaucoma Market Dynamics (Key Drivers and Barriers)

5. Glaucoma Market Opportunities

6. Glaucoma Therapeutic Approaches

7. Glaucoma Pipeline Analysis

8. Glaucoma Current Treatment Practices/Algorithm

9. Impact of Emerging Therapies on the Glaucoma Market

Table of Contents

1. Key Insights

2. Executive Summary

3. Glaucoma Competitive Intelligence Analysis

4. Glaucoma Market Overview at a Glance

5. Glaucoma Disease Background and Overview

6. Glaucoma Patient Journey

7. Glaucoma Epidemiology and Patient Population

8. Glaucoma Treatment Algorithm, Current Treatment, and Medical Practices

9. Glaucoma Unmet Needs

10. Key Endpoints of Glaucoma Treatment

11. Glaucoma Marketed Products

12. Glaucoma Emerging Therapies

13. Glaucoma Seven Major Market Analysis

14. Attribute Analysis

15. Glaucoma Market Outlook (7 major markets)

16. Glaucoma Access and Reimbursement Overview

17. KOL Views on the Glaucoma Market

18. Glaucoma Market Drivers

19. Glaucoma Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

About DelveInsight

DelveInsight is a leading Life Science market research and business consulting company recognized for its off-the-shelf syndicated market research reports and customized solutions to firms in the healthcare sector.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=glaucoma-treatment-market-2034-ema-pdma-fda-approvals-clinical-trials-medication-therapies-nice-approvals-prevalence-and-companies-by-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/consulting

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.